---
title: "Protagenic Therapeutics FY 2026: Net income $1.37M, EPS $0.59— 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295968443.md"
description: "Protagenic Therapeutics reported a net income of $1.37M and EPS of $0.59 for FY2026, reversing a prior-year loss due to a $7.31M gain on subsidiary disposal. The company is focusing on PT00114 development, implemented cost-cutting measures reducing expenses by ~$8M, and lost its Nasdaq listing, now trading on OTCQB. Cash reserves are expected to last only through Q3 2026, necessitating additional capital."
datetime: "2026-08-14T19:45:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295968443.md)
  - [en](https://longbridge.com/en/news/295968443.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295968443.md)
generator: "portal-rs"
---

# Protagenic Therapeutics FY 2026: Net income $1.37M, EPS $0.59— 10-K Summary

Protagenic Therapeutics reported net income of $1.37M for the year ended March 31, 2026, versus a loss of $(3.59M) in the prior year, driven largely by a $7.31M gain on disposal of a subsidiary. Diluted earnings per share were $0.59 for FY 2026 compared with $(0.67) in FY 2025.

**Financial Highlights**

-   Net income was $1.37M for the year ended Mar 31, 2026, versus a $(3.59M) loss for the year ended Mar 31, 2025 (turnaround driven by $7.31M gain on disposal of subsidiary).
-   Diluted earnings per share were $0.59 for the year ended Mar 31, 2026, versus $(0.67) for the year ended Mar 31, 2025.

**Business Highlights**

-   Clinical program focus: The company is prioritizing development of PT00114, having completed Phase I dosing and planning Phase Ib/IIa milestones through 2027.
-   Operational restructuring: Management implemented cost-cutting and moved to a virtual operating model, reducing annualized expenses by roughly $8M and concentrating resources on the lead program.
-   Pipeline change and unwind: Protagenic briefly acquired five preclinical assets via a merger with Phytanix, then unwound the transaction and returned the assets to the sellers.
-   Liquidity runway: Cash is expected to fund operations only through Q3 2026, creating an urgent need for additional capital or strategic partnerships.
-   Regulatory and listing status: The company is refiling an IND for PT00114; its Nasdaq listing was lost and shares now trade on the OTCQB, which may affect market access and liquidity.

Original SEC Filing: Protagenic Therapeutics, Inc.\\new \[ PTIX \] - 10-K - Aug. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PTIX.US](https://longbridge.com/en/quote/PTIX.US.md)
- [PTIXW.US](https://longbridge.com/en/quote/PTIXW.US.md)

## Related News & Research

- [Quanta Services announces dividend of R$ 0.03 per unit for Q3 2026](https://longbridge.com/en/news/297931955.md)
- [LyondellBasell announces dividend of R$ 1.72 per unit for 3Q 2026](https://longbridge.com/en/news/297814383.md)
- [PulteGroup declares Q3 2026 dividend of R$ 0.9 per unit](https://longbridge.com/en/news/297931957.md)
- [Marisa updates financial events calendar for 2026](https://longbridge.com/en/news/297913424.md)
- [J.M. Smucker announces dividend of R$ 1.94 per unit for Q3 2026](https://longbridge.com/en/news/297931100.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**